Astegolimab

艾特利单抗

Report date: 2026/05/21 20:00:22

Base Information

Drug NameAstegolimab
Drug Alias NameRG6149RO718807MSTT1041AAMG282AMG-282 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-1 receptor-like 1 inhibitors
TargetsInterleukin-1 receptor-like 1
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Dermatitis, AtopicPulmonary Disease, Chronic Obstructive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[42] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAmgen IncF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche LtdGenentech IncRoche (China) Holding Ltd
Inactive CompaniesUniversity Of Leicester
Active IndicationsPulmonary Disease, Chronic Obstructive
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Dermatitis, Atopic

Other Information

ATC CodeN/A
Related LinksN/A